When Pete Proimos was born with cystic fibrosis, he was only expected to live to 18. Not only did Proimos - now in his 40s - defy those expectations, he’s helping thousands of other people just like ...

“You should have told us that it (hosting the G20 summit) is such a difficult task, maybe we would have run away,” South African President Cyril Ramaphosa jokingly told Prime Minister Narendra Modi ...

Johannesburg: You should have told us that it (hosting the G20 summit) is such a difficult task, maybe we would have run away, South African President Cyril Ramaphosa jokingly told Prime Minister ...

Make sure not to miss this valuable item your first time around. When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. Add us as a preferred source on ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

I’m your average techie millennial who saw the dotcom bubble burst and was around when many of the OG services of the internet era simply vanished. Let’s just say, watching favorites like GeoCities ...

There are various popular options for free website hosting, but for developers who are already familiar with Git and the GitHub ecosystem it simply makes sense to use GitHub Pages. This quick GitHub ...

A tax and accounting-focused cloud and managed IT provider scores 85/100 in satisfaction, nearly triple its nearest competitor, winning top badges for "Best Usability," "Easiest Setup," and "Best ...

Despite a sharp drop in the previous session following the FDA rejection of its skin cancer drug RP1, Replimune (NASDAQ:REPL) shares bounced back on Wednesday even as multiple Wall Street analysts ...

NEW YORK--(BUSINESS WIRE)--Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Replimune Group, Inc. (NASDAQ: REPL) for potential violations of the federal ...

Replimune (NASDAQ:REPL) announced on Tuesday that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter regarding its marketing application for its lead asset, RP1, declining ...